NCT04800822 2026-06-04PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT03737994 2026-04-23Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Terminated10 enrolled 17 charts